← Back to Search

Monoclonal Antibodies

Humanized 3F8 Monoclonal Antibody (Hu3F8) for Neuroblastoma

Phase 1

Waitlist Available

Led By Ellen Basu, MD,PhD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing an experimental drug, Hu3F8, to see if it is safe and effective in treating neuroblastoma and other cancers.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

maximum tolerated dosage (MTD)

Secondary outcome measures

To assess activity of hu3F8 against NB and other GD2-positive tumors.

To quantitate pain during hu3F8 treatment

pharmacokinetics of hu3F8

Trial Design

1Treatment groups

Experimental Treatment

Group I: Humanized 3F8 Monoclonal Antibody (Hu3F8)Experimental Treatment1 Intervention

This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Naxitamab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Band of ParentsUNKNOWN

Y-mAbs TherapeuticsIndustry Sponsor

25 Previous Clinical Trials

1,489 Total Patients Enrolled

12 Trials studying Neuroblastoma

1,124 Patients Enrolled for Neuroblastoma

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,934 Previous Clinical Trials

588,742 Total Patients Enrolled

49 Trials studying Neuroblastoma

5,723 Patients Enrolled for Neuroblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical study recruiting participants currently?

"Per the information on clinicaltrials.gov, this specific experiment is not presently in search of individuals for testing purposes. The examination was initially posted on August 1st 2011 and its most recent update took place on August 24th 2022; however, 168 other trials are currently admitting participants."

Answered by AI

What precedent has been established with regards to Humanized 3F8 Monoclonal Antibody (Hu3F8) in clinical research?

"Currently, there are 7 ongoing medical trials investigating Humanized 3F8 Monoclonal Antibody (Hu3F8), none of which currently reside in Phase 3. 32 different institutions across the USA are conducting research on Hu3F8 and many of these facilities can be found within New york City."

Answered by AI

How many volunteers have signed up for the clinical trial thus far?

"Regrettably, no participants are being accepted for this trial at present. It was initially posted on August 1st 2011 and its last edit occurred on the 24th of August 2022. If you require a different medical study, 161 trials recruiting those with neuroblastoma or 7 studies involving Humanized 3F8 Monoclonal Antibody (Hu3F8) may be suitable options."

Answered by AI

Has something similar to this clinical experiment ever been conducted previously?

"Investigated since 2011, Humanized 3F8 Monoclonal Antibody (Hu3F8) was initially tested in a trial overseen by Y-mAbs Therapeutics that saw 68 participants. Subsequently receiving Phase 1 drug approval, there are now seven experiments focusing on Hu3F8 across 9 different nations and 8 cities."

Answered by AI

Is there a risk to administering Humanized 3F8 Monoclonal Antibody (Hu3F8) treatments?

"Our experts at Power rate the safety of Humanized 3F8 Monoclonal Antibody (Hu3F8) as a 1, indicating that there is only minimal evidence to suggest its efficacy and limited data on its effects in humans."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

2011. "Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01419834.